Physician profile
Clinton E Hull
NPI 1437232717
$2,195.97
in general payments reported to CMS, 2019-2025
23 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $193 · 2021: $275 · 2022: $351 · 2023: $61.48 · 2024: $806 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $814 · Consulting Fee: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $814.45 |
| Consulting Fee | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $486.32 | 2019-2025 | |
| Glaxosmithkline, LLC. | $300.00 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $263.25 | 2024 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $216.72 | 2019-2025 | Eliquis, Camzyos |
| Vifor Pharma, INC. | $190.24 | 2019-2022 | |
| Abbvie INC. | $136.94 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $89.58 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $71.86 | 2019-2022 | |
| Melinta Therapeutics, LLC | $65.02 | 2024 | Rezzayo, Kimyrsa |
| Astrazeneca Pharmaceuticals Lp | $59.96 | 2019-2022 | |
| Boston Scientific Corporation | $56.86 | 2025 | Watchman Access System |
| Mylan Specialty L.P. | $38.70 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $35.64 | 2024 | Uptravi |
| Kiniksa Pharmaceuticals International, Plc | $29.41 | 2024 | Arcalyst |
| Pulmonx Corporation | $26.03 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $23.14 | 2024 | Terlivaz |
| Biofire Diagnostics, LLC | $22.20 | 2019 | |
| Paratek Pharmaceuticals, INC. | $17.00 | 2019 | |
| Nabriva Therapeutics, Plc | $14.64 | 2020 | |
| Gilead Sciences, INC. | $14.62 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.95 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.52 | 2020 | |
| Allergan, INC. | $11.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clinton Hull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.